Drugs with this side effect
- 2-hydroxysuccinaldehyde: postmarketing
- 4-PBA: common
- 4-methylpyrazole
- 5-ASA: postmarketing
- 5-FU
- 5-aminolevulinic acid
- 5-aza-2'-deoxycytidine: 22% - 81.9%
- 5-azacytidine: very common, 2.3% - 69.5%
- 5-fluorocytosine
- 6-mercaptopurine
- 68Ga
- A77 1726
- APAs
- Anidulafungin: 7.31% - 16%
- BCNU: 1-10%
- BPTI
- Benicar-HCT
- Bivalirudin: postmarketing
- CAS 76095-16-4
- CAS 76420-72-9
- CGP 19835A: very common
- Cancidas: uncommon, 0% - 11%
- Carfilzomib: 1.33% - 46.8%
- D-penicillamine
- EDTA
- FAMP
- FK463: 2.5% - 51.2%
- FdUrd
- Fe(III
- Forteo
- Ge-132: 2%
- Glat copolymer: infrequent
- Goserelin: 0% - 1-10%
- Histrelin
- ICI 182,780: 4.5% - 5%
- K779: postmarketing, 0% - 35%
- L-Dmp: infrequent
- LMWH: 0% - 16%
- LY146032: postmarketing, common, 2.1% - 15.5%
- Leuprorelin: 5%
- Lisinopril: very rare, postmarketing
- Meropenem anhydrous: 5.5%
- N-carbamylglutamate
- NSC 352122
- Nuvocid
- Octreotide
- PCI-32765
- PGE1
- Photofrin: 28% - 32%
- Photofrin II
- Promacta
- Refludan: 1.1% - 13.1%
- Revasc: 0.676% - 6.39%
- Romidepsin: 2.94% - 72.3%
- SOM230: 4%
- SU5416
- Signifor: 4%
- TMC435: 11%
- TR-700
- Triptorelin: 1.4%
- UDCA: postmarketing
- VACV: 0% - 12%
- Vancocine
- ZnCl2
- abacavir
- abacavir-lamivudine: uncommon
- abiraterone
- acamprosate: infrequent
- acetaminophen: 2.7%
- acetohydroxamic acid
- actinomycin D
- acyclovir: very rare
- adefovir dipivoxil
- alendronate
- aliskiren
- allopurinol: postmarketing
- alpha-methyl-p-tyrosine
- alvimopan
- ambrisentan: postmarketing
- amikacin
- aminoglutethimide
- amoxicillin: postmarketing
- amphotericin B: 26.7% - 47.9%
- ampicillin
- amsacrine: 1-10%
- anagrelide: 1-5%
- anastrozole: 3.65% - 5.14%
- anthracycline
- apixaban: common, 2.58% - 3.01%
- aprepitant: 0% - 4.3%
- aripiprazole
- arsenic
- arsenic trioxide: common
- asenapine
- aspirin
- atorvastatin
- atovaquone: 0% - 9%
- auranofin: postmarketing, 1.6% - 3.1%
- axitinib: 4%
- azathioprine: uncommon
- azithromycin
- aztreonam
- baclofen
- balsalazide: 3.7%
- belinostat: 11% - 32%
- bendamustine: 19%
- betaxolol
- bexarotene: 5.95% - 24.5%
- bezafibrate: 1.1%
- bicalutamide: 7%
- bleomycin hydrochloride
- boceprevir: very common, 20% - 30%
- bortezomib: 0% - 37%
- bosentan: postmarketing, common, 8%
- bosutinib: 12.3% - 27.4%
- bromcresol green
- budesonide
- bupivacaine: 8.17% - 12%
- bupropion: postmarketing, rare
- busulfan
- cabazitaxel: 5% - 97.3%
- candesartan: postmarketing
- candesartan cilexetil
- capecitabine: 1% - 83%
- captopril
- carbamazepine: very rare
- carbenicillin
- carbidopa
- carboplatin: 71% - 90%
- carnitine: 3% - 12%
- carvedilol: 2% - 2.4%
- cefazolin: postmarketing
- cefepime: postmarketing
- cefoxitin
- cefpodoxime
- ceftaroline
- ceftizoxime
- ceftobiprole
- ceftriaxone: 0.1 - 1.0%
- celecoxib
- cerivastatin
- cevimeline
- chlorambucil
- cidofovir: postmarketing, 24.3%
- cilazapril
- cilostazol
- cinacalcet: 5.88% - 17.2%
- ciprofloxacin: postmarketing, rare
- cisplatin
- citalopram: postmarketing, infrequent, uncommon
- cladribine: very common, 1%
- clarithromycin
- clindamycin
- clobazam: postmarketing
- clodronate
- clofarabine: 75.4% - 83.3%
- clofazimine
- clomipramine: 2%
- clonazepam
- clopidogrel: very rare, postmarketing
- clozapine
- colchicine: postmarketing
- colestyramine
- conivaptan
- copolymer 1
- copper
- crizotinib
- cyclophosphamide
- cyproterone
- cyproterone acetate
- cysteamine
- cytarabine: 1% - 18.2%
- d-telaprevir: 17%
- dabigatran etexilate
- dabrafenib: 0% - 55%
- dalbavancin
- dalteparin: 0% - 1.34%
- dantrolene
- darunavir
- dasatinib: 3% - 75%
- deferasirox: postmarketing
- degarelix
- delamanid
- delavirdine
- deprenyl: infrequent, 0%
- dexmedetomidine: postmarketing, 2% - 3%
- dexrazoxane
- diatrizoate
- diazepam
- diclofenac: very rare
- dicloxacillin
- didanosine: postmarketing
- dipyridamole
- docetaxel: 1% - 96.8%
- dolasetron
- donepezil: infrequent, frequent
- doripenem: 1% - 10%
- doxepin: infrequent
- doxercalciferol
- doxorubicin: uncommon, very common, 0% - 72.2%
- doxycycline
- duloxetine: infrequent
- efavirenz
- eletriptan: rare
- eltrombopag
- emtricitabine: postmarketing, uncommon, 7% - 9.5%
- eplerenone
- eribulin: 2% - 58%
- ertapenem: 5.7% - 6.9%
- eslicarbazepine acetate
- esomeprazole magnesium
- estramustine phosphate
- etidronate
- etodolac
- etoposide: 0 to 33 - 72%
- etoposide phosphate
- etoricoxib
- etravirine
- everolimus: common, very common, 0% - 61%
- ezetimibe
- famciclovir: 0.1%
- famotidine
- febuxostat
- felbamate
- felodipine
- fenofibrate: postmarketing
- fenofibric acid: postmarketing
- fentanyl: common, 9.09% - 31.6%
- fidaxomicin: 2% - 2.48%
- flucloxacillin
- fluconazole
- fludarabine
- fluoxetine: infrequent
- flurbiprofen
- flutamide
- fluvoxamine: rare, infrequent
- fondaparinux: uncommon, common, 0.272% - 19.6%
- fosaprepitant
- fosaprepitant dimeglumine: 0% - 4.3%
- foscarnet: 0.14% - 15%
- fosinopril
- fosinoprilat
- fosphenytoin: infrequent
- fotemustine
- furosemide
- fusidic acid
- gabapentin: postmarketing, infrequent
- gadobenate dimeglumine
- galantamine: 3%
- ganciclovir: 16.8% - 19.7%
- gefitinib
- gemcitabine: very common, 0% - 86%
- gemfibrozil
- gemifloxacin
- gentamicin
- glibenclamide
- gliclazide
- glimepiride
- granisetron: 4% - 9.4%
- guanidinium
- haloperidol
- hetastarch: postmarketing
- hexamethylmelamine
- histamine
- hydralazine: uncommon
- hydrochlorothiazide
- hydroxybutyrate
- hydroxychloroquine
- hydroxyurea: common
- ibandronate
- ibuprofen: 2.3% - 16.7%
- icodextrin
- idarubicin
- ifosfamide
- iloperidone
- imatinib: postmarketing, very common, 0% - 42%
- indacaterol
- indapamide: postmarketing
- indinavir: 0.6% - 2.1%
- indomethacin
- iodide
- irbesartan: rare
- irbesartan-hydrochlorothiazide
- irinotecan: 2.1% - 98.6%
- isosorbide-5-mononitrate
- isradipine
- ivermectin
- ixabepilone: 1% - 8%
- ketoprofen
- ketorolac
- ketorolac tromethamine
- lacosamide
- lamivudine: postmarketing, uncommon, 1% - 4%
- lamotrigine: rare, infrequent
- lanreotide: 3.45% - 14.8%
- lansoprazole
- lapatinib: 0% - 10%
- lasofoxifene: uncommon
- leflunomide: uncommon
- lenalidomide: postmarketing, common, 6.1% - 31.4%
- lercanidipine: uncommon
- leuprorelin acetate
- levodopa/carbidopa
- levonorgestrel
- linezolid: postmarketing, 0% - 7.1%
- lithium carbonate
- lomefloxacin
- lomitapide
- losartan: postmarketing, 14%
- lurasidone: infrequent
- mTHPC: common
- macitentan: 13%
- maraviroc
- medroxyprogesterone: postmarketing
- medroxyprogesterone acetate: postmarketing
- mefenamic acid
- megestrol: 0% - 5%
- meloxicam: 0% - 4.1%
- melphalan: very common
- memantine: frequent
- mephenytoin
- meropenem: 5.5%
- mesna
- methotrexate
- methylphenidate: very rare, postmarketing
- metolazone
- mianserin
- miconazole: 1.7% - 2.8%
- mirtazapine: postmarketing, rare
- misoprostol: postmarketing
- mitomycin C
- mitotane
- mitoxantrone: 6% - 5-75%
- modafinil
- morphine: 2%
- moxifloxacin
- mycophenolate mofetil: 3.4% - 53%
- mycophenolic acid: 21.6% - 53%
- nabilone
- nabumetone: postmarketing, 0.5%
- naproxen
- naratriptan: rare
- nefazodone: infrequent
- nelarabine: 10% - 99%
- nelfinavir: 0% - 2.56%
- nevirapine: postmarketing, uncommon, 7% - 7.3%
- nifedipine
- nilotinib: common, 4% - 27%
- nilutamide
- nimodipine
- nisoldipine
- nitazoxanide
- nitrofurantoin
- nizatidine
- ofatumumab: 5% - 17%
- ofloxacin: postmarketing
- olanzapine: infrequent
- olmesartan
- olsalazine
- omeprazole: postmarketing
- oseltamivir
- oxaliplatin: very common, 0.1% - 85.2%
- oxaprozin
- oxycodone
- paclitaxel: uncommon, very common, 4% - 97%
- paliperidone
- palonosetron
- pamidronate: postmarketing, common, 0% - 47.8%
- pantoprazole: rare
- paricalcitol
- paroxetine: infrequent, uncommon
- pazopanib
- pemetrexed: 0% - 33%
- penciclovir: 0.1%
- pentamidine
- pentastarch
- pentosan polysulfate
- pentostatin: 5% - 35%
- pentoxifylline
- pergolide: frequent, 1.1%
- perindopril
- perindopril erbumine: postmarketing
- perindoprilat: postmarketing
- phenylbutyric acid: 9%
- phenytoin: infrequent
- pimozide: postmarketing
- pioglitazone
- piperacillin
- piroxicam
- pixantrone
- pomalidomide: 20.5% - 45.7%
- ponatinib: 9% - 55%
- posaconazole: 1.91% - 14.2%
- pralatrexate
- pramipexole
- prasugrel
- pravastatin: postmarketing
- prednisone
- pregabalin: infrequent
- primidone
- probenecid
- procarbazine
- progesterone
- propafenone: postmarketing
- prostacyclin: postmarketing
- quetiapine: infrequent
- rabeprazole
- radium: 2% - 93%
- raltegravir
- raltitrexed: 12-19%
- ranitidine
- rapamycin: very common, 21% - 37%
- rasagiline
- rasburicase
- reboxetine
- regorafenib: 79%
- remifentanil: 0% - 2.84%
- retinoic acid: postmarketing
- ribavirin: common, very common, 0.6-0.8% - 35%
- rifabutin: 6%
- rifampicin
- rifapentine
- rifaximin: 7.86%
- riluzole: infrequent
- riociguat: 7%
- risedronate
- risperidone: infrequent, 0.1% - 1%
- ritonavir: 4%
- rivaroxaban
- rivastigmine: frequent
- ropinirole: infrequent, 2%
- ropivacaine: 0.2% - 13.8%
- rosiglitazone: common, 7.1%
- rufinamide: frequent
- ruxolitinib: very common, 11% - 96.1%
- salmon calcitonin acetate
- samarium
- saquinavir: common
- sertraline: rare
- sibutramine
- sildenafil
- simvastatin: postmarketing
- sitaxsentan: uncommon
- sodium cromoglycate
- sodium ferric gluconate
- sofosbuvir: common, very common, 0% - 21%
- sorafenib: postmarketing, common
- stavudine: postmarketing, rare
- streptozotocin
- sulfasalazine
- sulindac
- sumatriptan: rare
- sunitinib: 2%
- tacrolimus: common, 1% - 50%
- tamoxifen: 3.65% - 5.14%
- telavancin: uncommon
- telithromycin
- telmisartan: postmarketing, rare, uncommon
- temozolomide: uncommon, common, 1% - 2%
- temsirolimus
- teniposide: 88%
- tenofovir disoproxil fumarate
- tenoxicam
- terbinafine: postmarketing
- testosterone: postmarketing, 2.47% - 2.5%
- thalidomide: 0% - 14.5%
- thioridazine: postmarketing
- thiotepa
- tiagabine: infrequent
- tiaprofenic acid
- tigecycline: 4.2% - 6%
- tiopronin
- tipranavir: uncommon, 0% - 2.3%
- tizanidine: infrequent
- tobramycin
- tofacitinib
- tolcapone: infrequent
- topiramate: frequent, 0.8% - 3%
- topotecan: very common, 1.9% - 98%
- trabectedin
- tramadol: postmarketing, uncommon
- trametinib: 0% - 55%
- trandolapril
- tranexamic acid: 5.6%
- tranylcypromine
- trazodone
- treprostinil
- trimetrexate: 0% - 15.3%
- troglitazone: postmarketing
- trovafloxacin
- v 1784: postmarketing, uncommon, common
- valdecoxib
- valganciclovir: 8% - 26%
- valproate: postmarketing
- valrubicin
- varenicline: infrequent
- venlafaxine: infrequent
- verteporfin
- vigabatrin: common
- vinblastine
- vincristine: 16.9% - 34%
- vinflunine
- vinorelbine: 1% - 87%
- vitamin D2
- vorapaxar: 5%
- voriconazole: common, 0% - 2.7%
- vorinostat
- warfarin
- zalcitabine
- zaleplon: infrequent
- zidovudine: common, 1% - 2%
- zidovudine/lamivudine
- ziprasidone: infrequent
- zoledronic acid: postmarketing, common, 4.4% - 22%
- zolpidem: rare
- zonisamide: infrequent
- zopiclone: infrequent
|
Drugs with this indication
|